Boehringer Ingelheim and Zai Lab Partner on DLL3-Targeting Combo Therapy for Small Cell Lung Cancer
Event summary
- Boehringer Ingelheim and Zai Lab launch a Phase Ib/II study to evaluate the combination of obrixtamig (DLL3/CD3 T-cell engager) and zocilurtatug pelitecan (DLL3-targeting ADC) in small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs).
- The study will enroll patients with poorly differentiated NECs and extensive stage SCLC (ES-SCLC), diseases with high unmet medical needs.
- Zai Lab will supply its DLL3-targeting ADC for the study, while Boehringer Ingelheim will sponsor and oversee clinical operations.
- Both obrixtamig and zocilurtatug pelitecan have received FDA Fast Track and Orphan Drug Designations for SCLC.
The big picture
This collaboration aligns with Boehringer Ingelheim's immuno-oncology strategy and Zai Lab's focus on advancing smart combinations for hard-to-treat cancers. The partnership leverages the strengths of both companies in targeting DLL3, a validated therapeutic target for SCLC. The deal underscores the growing trend of strategic collaborations in oncology to accelerate the development of innovative therapies for patients with high unmet medical needs.
What we're watching
- Clinical Efficacy
- How the combination of obrixtamig and zocilurtatug pelitecan will perform in terms of safety and initial clinical activity in SCLC and NECs.
- Regulatory Progress
- The pace at which both obrixtamig and zocilurtatug pelitecan advance through their respective global Phase III trials.
- Market Impact
- Whether this collaboration will position Boehringer Ingelheim and Zai Lab as leaders in the DLL3-targeting space for SCLC and NECs.
Related topics